OBJECTIVES: The aim of this study was to describe the total treatment costs related to Crohn’s Disease treatment with biologics and to evaluate these costs based on the most prevalent weight range. METHODS: A cost-minimization analysis was performed among adalimumab-subcutaneous (ADA) and infliximab-intravenous (IFX) to compare the total treatment costs in Crohn's disease according to the Brazilian Private HealthCare System perspective. Total treatment cost was calculated based on the dose per application, number of vial/syringe, cost of application and median and range of weight. These inputs were based on scientific literature. Yearly treatment cost was calculated for patients with a median of 68kg, according to doses defined in product labels. A cost analysis for a weight range was performed.  Drug prices were based on Factory Prices plus 18% taxes (CMED source). An univariate analysis was performed to determine the impact on results. RESULTS: The median patient weight used in this analysis was 68±4,08kg (Weight range: 64 to 72kg - normal distribution). For IFX the Medication Cost was R$92.478,12, Application Cost was R$2.360,33 and the Total Treatment Cost was R$94.838,45. For ADA the Medication Cost was R$85.807,15, Application Cost was R$3.788,98 and the Total Treatment Cost was R$89.596,13. Comparing the scenario with IFX and ADA, the treatment with ADA presented a savings of R$5.242,32 per patient/year. The weight interval cost analysis presented a savings for ADA of R$5.242,32 per patient/year in a range of 64 to 72kg. In sensitivity analysis ADA presented economic savings in most scenarios, the variation of IFX vial and ADA syringe costs are important factors that could modify the sensitivity analysis. CONCLUSIONS: The treatment of Crohn’s disease with ADA compared to IFX presented an economic savings for nearly 68% of patients with Crohn’s Disease in the Brazilian Private HealthCare System.